Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gitlab Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.59 (market cap $39.89B), while Gitlab Inc trades at $33.77 (market cap $5.48B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.3× Gitlab Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GTLB | |
|---|---|---|
Market Cap | $39.89B | $5.48B |
Sector | Health | Technology |
52-Week High | $491.22 | $51.04 |
52-Week Low | $278.09 | $19.42 |
Enterprise Value | $38.15B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GitLab (GTLB) trades at $32.42, down 4.25% today, but maintains a bullish technical outlook with strong moving average signals. The company shows impressive revenue growth, reaching $759 million in 2025, with consistent earnings beats in recent quarters. Analyst sentiment is mixed with 36.7% buy ratings, while the stock trades near consensus price target of $31.93. Recent news highlights GitLab's leadership in DevSecOps and strategic AI partnerships.
GitLab presents a growth story with strong market positioning but faces profitability challenges. The stock offers upside potential from AI-driven software demand and enterprise adoption, though high valuation multiples and negative cash flow pose risks. Investors should weigh the company's strategic position against its path to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
